Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
Cytosorbents' Q1 call set operating cash flow breakeven for 2H 2026 and a DrugSorb-ATR de novo submission in late 2026/early 2027. The DOAC removal market offers upside if the FDA clears the device.
The Q1 2026 earnings call presentation is the first detailed update on Turtle Beach's performance. Post-call analyst revisions now become the next trigger for the stock.
The chipmaker's sharp gains since late March have outpaced the broader market, raising valuation concerns. A pullback would likely weigh on QQQ, where the article's author is long.
Leslie’s Q2 comparable sales rose 6.6% as the Price Drop campaign lifted traffic. Full-year guidance of $1.1B-$1.25B sales and $55M-$75M EBITDA was reiterated. Cost headwinds flagged for the back half.
Identiv, Inc. (NASDAQ:INVE) published its Q1 2026 earnings call slide deck. The presentation arrives as the company pivots toward IoT and RFID solutions, making revenue mix and margin trends the key watchpoints.
The pool-supply retailer’s revenue jump of $22.23 million above consensus masks a widening adjusted loss per share of $5.36, leaving the turnaround thesis at a crossroads.
Nebius Group shares surged 16% to $207.79 after Q1 results and a 1.2 GW Pennsylvania AI factory deal. The announcement signals accelerating demand for dedicated AI compute infrastructure.
Revenue growth accelerated in Q1 as customer expansion in Europe and Asia Pacific shifted the geographic mix. The next quarter's regional breakdown will test whether the acceleration is durable.
Haley Sacks, the 'Mrs. Dow Jones' with over a million followers, pushes salary negotiation and investing over saving. The next test is whether her book drives measurable retail ETF buying.
High-purity KrF photoresist resin developed via AI platform enters customer validation with Hengkun New Materials, challenging JSR, TOK, and DuPont's supply dominance.
Nifty's break below the 23,650 max pain strike signals a shift in options positioning that could define the weekly expiry range. The next test is whether put writers defend lower strikes.
$TELA’s Europe revenue climbed 41%, and the OviTex LTR rollout provides a $20M Q2 guide that becomes the next concrete catalyst for the 8%+ full-year growth target.
AEP's $2.6 billion common stock offering uses forward sale agreements, increasing float immediately. The pricing and settlement dates will determine the dilution overhang.
A hotter-than-expected inflation print forces a repricing of Fed rate cuts, while gold, oil, and miners rally. The Trump-Xi meeting on Thursday adds a binary risk event.
Kyivstar Group reported full-year revenue of $1.15M. The release left profit, cash-flow, and balance-sheet questions unanswered, setting up the next catalyst.
A Seeking Alpha analyst upgraded SoFi to Strong Buy, citing diversified prospects that outweigh near-term credit headwinds. The Alpha Score sits at 21.
RB Global (RBA) carries a Mixed Alpha Score of 37, entirely separate from the AIRR ETF’s re-industrialization thesis. Confusing the two can skew industrial exposure decisions.
Stock futures fell as traders weighed renewed U.S.-Iran tensions and the looming April CPI report. PLUG and HIMS led pre-market volume. The inflation print will reset rate bets for growth stocks.
Revenue miss and NAV decline forced the cut to $0.035. The next test is whether Q4 net investment income covers the new payout.
Rigetti Computing posted its Q1 2026 earnings call presentation, giving investors the first structured look at financials and technology milestones. The deck will be scrutinized for cash runway, revenue growth, and quantum processor roadmap updates.
Exagen's Q1 2026 slide deck is now public. Investors will parse AVISE test volumes, average revenue per test, and cash runway for signals on the path to breakeven.
Samsung+SK Hynix 42% of Kospi; TSMC >40% of Taiex. Goldman’s Moe: supply shock could force correction. Allocators risk doubling AI exposure.
The FLKR rally leans heavily on Samsung (roughly 25% of assets) and memory chip momentum. A guidance miss or North Korea shock could reverse gains.
The SBIR award validates GSI’s G-II chip for counter-drone use; Phase I contracts rarely translate to near-term revenue. The stock’s move may be premature.
First-quarter revenue beat expectations on $49 billion in assets. Cost reductions won't show until the second half, creating a margin lag that the next quarterly report will test.
FG-3246 Phase II interim data due Q4 2026; roxadustat Phase III results in 2H 2026. Cash extended to 2028 removes dilution overhang, setting up a two-catalyst year.
Founder Jonah Peretti exits as CEO. The cash infusion addresses near-term liquidity, while the implied valuation signals deep distress. Next catalyst: closing timeline and Allen's first strategic remarks.
Anthropic's Mythos has crushed most cybersecurity stocks in 2026, but CrowdStrike's premium valuation has held. The next earnings report will test the durability of that confidence.
NAB's relative strength against the ASX 200 matters more for the banking sector than a single stock call. The next valuation check is the half-year report, where bad-debt charges will test the thesis.
Phibro Animal Health's fiscal Q3 2026 slide deck is out, offering segment-level detail on Animal Health, Mineral Nutrition, and Performance Products. Investors should focus on margin trends and updated full-year guidance for the June year-end.